DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.
Talk to the deal team
Bradford A. Adams
Managing Director
Boston, United StatesOaklins TM Capital
Michael S. Goldman
Managing Director
New York, United StatesOaklins TM Capital
James McLaren
Managing Director
New York, United StatesOaklins TM Capital
Related deals
Zoofy has raised growth capital for its expansion into Germany
Zoofy, an Amsterdam-based platform connecting professional handymen with consumers and businesses, has raised growth capital from a private investor for its expansion into Germany. The company expects to launch its German platform in the second quarter of this year.
Learn moreAce Pharmaceuticals has been acquired by Gilde Buy Out Partners, Gilde Healthcare and Quadrum Capital
Ace Pharmaceuticals BV has been acquired by Gilde Buy Out Partners, Gilde Healthcare, Quadrum Capital and the management team.
Learn moreInside Pensions has been acquired by ZEDRA Group
The owners of Inside Pension Ltd. have sold the business to ZEDRA Group.
Learn more